Relay Therapeutics

Relay Therapeutics is a Cambridge, Massachusetts clinical-stage precision medicines company (NASDAQ: RLAY) using protein motion to drug historically intractable oncology and genetic-disease targets. Its Dynamo platform combines full-length protein engineering, cryo-EM, ambient-temperature X-ray crystallography, long-timescale molecular dynamics, machine learning, virtual screening, activity- and ligand-based screening, and an ML-powered DNA-encoded library (REL-DEL) to design molecules against conformational states that static structures miss. The clinical pipeline is led by zovegalisib (RLY-2608), described as the first allosteric, pan-mutant, isoform-selective PI3K-alpha inhibitor, in Phase 3 for HR+/HER2- breast cancer and Phase 1/2 for vascular anomalies and PROS; RLY-8161, an NRAS- selective inhibitor, is in Phase 1/2 for NRAS-mutant solid tumors; an alpha-galactosidase A non-inhibitory chaperone for Fabry disease is in discovery; lirafugratinib (RLY-4008, FGFR2) was out-licensed to Elevar Therapeutics in December 2024. Relay has no public developer API, SDK, or open-source release; the Dynamo platform is proprietary internal R&D tooling, and the company's GitHub organization currently has no public repositories. The commercial surface is therapeutic candidates, clinical partnerships, and out-licensing rather than data products.

Relay Therapeutics is profiled on the APIs.io network. Tagged areas include Drug Discovery, Precision Medicine, Oncology, Genetic Disease, and Protein Motion.

Relay Therapeutics’ developer surface includes GitHub presence and 12 more developer resources.

🌐 Visit website 📡 Source on GitHub

7.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

Drug DiscoveryPrecision MedicineOncologyGenetic DiseaseProtein MotionComputational ChemistryMolecular DynamicsCryo-EMMachine LearningDNA-Encoded LibrariesAllosteric InhibitorsPI3K-AlphaNRASFGFR2Fabry DiseaseBiotechnologyClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.4/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/relay-tx: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Build 1

SDKs, sample code, and the tooling you integrate with

GitHub

GitHub

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 5

The organization behind the API

Website

Website

Careers

Careers

InvestorRelations

InvestorRelations

LinkedIn

Twitter

Twitter

Other 5

Properties that don't map to a standard resource type

Science

DynamoPlatform

Pipeline

Publications

Patients

Source (apis.yml)

aid: relay-tx
name: Relay Therapeutics
description: 'Relay Therapeutics is a Cambridge, Massachusetts clinical-stage precision medicines company (NASDAQ: RLAY) using
  protein motion to drug historically intractable oncology and genetic-disease targets. Its Dynamo platform combines full-length
  protein engineering, cryo-EM, ambient-temperature X-ray crystallography, long-timescale molecular dynamics, machine learning,
  virtual screening, activity- and ligand-based screening, and an ML-powered DNA-encoded library (REL-DEL) to design molecules
  against conformational states that static structures miss. The clinical pipeline is led by zovegalisib (RLY-2608), described
  as the first allosteric, pan-mutant, isoform-selective PI3K-alpha inhibitor, in Phase 3 for HR+/HER2- breast cancer and
  Phase 1/2 for vascular anomalies and PROS; RLY-8161, an NRAS- selective inhibitor, is in Phase 1/2 for NRAS-mutant solid
  tumors; an alpha-galactosidase A non-inhibitory chaperone for Fabry disease is in discovery; lirafugratinib (RLY-4008, FGFR2)
  was out-licensed to Elevar Therapeutics in December 2024. Relay has no public developer API, SDK, or open-source release;
  the Dynamo platform is proprietary internal R&D tooling, and the company''s GitHub organization currently has no public
  repositories. The commercial surface is therapeutic candidates, clinical partnerships, and out-licensing rather than data
  products.'
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/relay-tx.png
tags:
- Drug Discovery
- Precision Medicine
- Oncology
- Genetic Disease
- Protein Motion
- Computational Chemistry
- Molecular Dynamics
- Cryo-EM
- Machine Learning
- DNA-Encoded Libraries
- Allosteric Inhibitors
- PI3K-Alpha
- NRAS
- FGFR2
- Fabry Disease
- Biotechnology
- Clinical Stage
url: https://raw.githubusercontent.com/api-evangelist/relay-tx/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/relay-tx-domain-security.yml
- type: Website
  url: https://relaytx.com
- type: Science
  url: https://relaytx.com/science/
- type: DynamoPlatform
  url: https://relaytx.com/dynamo-platform/
- type: Pipeline
  url: https://relaytx.com/pipeline/
- type: Publications
  url: https://relaytx.com/publications/
- type: Patients
  url: https://relaytx.com/patients/
- type: Careers
  url: https://relaytx.com/careers/
- type: Contact
  url: https://relaytx.com/contact/
- type: InvestorRelations
  url: https://ir.relaytx.com
- type: GitHub
  url: https://github.com/relaytx
- type: LinkedIn
  url: https://www.linkedin.com/company/relay-therapeutics/
- type: Twitter
  url: https://twitter.com/relaytx
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com